04:41 PM EDT, 06/04/2026 (MT Newswires) -- Gilead Sciences ( GILD ) and Lakefront Biotherapeutics (LKFT) said Thursday they have completed the acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.

Gilead acquired Ouro for about $1.68 billion and up to $500 million in contingent milestone payments, the companies said, adding that they will equally split the payments.

The acquisition adds gamgertamig to Gilead's inflammation portfolio and will be the foundation of Lakefront's clinical development pipeline, they said.